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Polycystic kidney disease (PKD) refers to a group of inherited disorders char-
acterized by the development and growth of renal cysts. Recent advances in
genomics have contributed to a better understanding of the pathogenesis of the
disease, suggesting new treatment strategies to inhibit or delay cyst formation
and expansion. The efficacy of these therapies is evaluated by estimation of
cystic burden measured by magnetic resonange imaging (MRI) as total kidney
volume (TKV). TKV is considered to be the best available biomarker of disease
progression and for this reason the development of imaging techniques that can
provide accurate and reliable quantitative information on the development of
renal cyst has become critical.
In this Thesis, different imaging approaches are proposed for a correct char-
acterization of the PKD patient by the estimation of renal and cyst volume
from magnetic resonance and computed tomography (CT) images. TKV esti-
mation method from MRI relies on a previously validated method developed for
axial images that has been adapted and validated to work on coronal images.
The choice of working on coronal images is motivated by the recommendation
provided by the Consortium of Renal Imaging Studies in Polycystic Kidney
Disease (CRISP) which are followed in several multicenter trials. The results
have been compared with the ones obtained from axial images and validated
with volume estimation obtained from manual tracing. The performace of the
semi-automated method in terms of misclassification of the PKD patient was
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also evaluated in comparison with other radiologic approaches currently used
for TKV assessment such as the ellipsoid method and the mid-slice method. A
novel method for TKV computation from CT images is proposed. This multi-
step approach is completely automated and includes preprocessing for data con-
ditioning, localization of the kidneys in the abdomen and the use of a level set
approach to identify the renal contour and so extrapolate the renal volume.
The segmented kidneys obtained with the developed methods where used to
initialize the segmentation of the cysts. In CT images the total cyst volume
(TCV) was obtained using a clustering approach based on the intensity of gray
levels. The same strategy was used for MR images with the addition of an
extra step to enable cyst counting. Every cyst agglomerate underwent a voting
mechanism based on the curvature of the object interface which allowed to dis-
tinguish the single cysts. Every cyst is indentified by its centroid that is used
for the initialization of a multi-phase level set. The results of this approach for
TCV computation was validated through comparison with TCV obtained by
manual segmentation.
Nowadays cystic burden is estimated as TKV using methods that rely on ge-
ometrical approximation. The proposed automated approaches allow fast and
accurate measurement of TKV but also TCV. TCV measurement provide a
more precise information on the stage of the disease, opening new paradigms
for diagnosis and monitoring of PKD progression.
The last chapter is dedicated to the research activity conducted in the area of
diffusion weighted imaging (DWI). DWI is an MRI method for studying Brow-
nian motion of water molecules in tissue, that has shown great potential in




Polycystic kidney disease is a group of inherited disorders identified by the de-
velopment and growth of cysts in both kidneys that cause progressive renal
function loss leading to end-stage renal failure. The most common is autoso-
mal dominant polycystic kidney disease (ADPKD). In recent years, advances
in studies on cystogenesis have led to novel targets for the treatment of PKD.
Imaging has become an important tool for diagnosis as for monitoring the evolu-
tion of the disease and different methods have been proposed during last years.
In this chapter are presented the clinical characteristics of ADPKD, the main
trials that are exploring the possibility of new clinical targets and the role of
imaging as an important tool for diagnosis and prognosis of the disease.
1.1 Autosomal dominant polycystic kidney dis-
ease
Autosomal polycystic kidney disease is an inherited, monogenic and multi-
systemic renal disorder. With an approximated incidence of 1:400 to 1:1000
[2] it is the most common genetic disease [3] and the fourth most common cause
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of end-stage renal disease (ESRD) [4]. ADPKD is characterized by the de-
velopment and the gradual expansion of cysts inside both kidneys (figure 1.1)
and is due to the mutation of one of two genes, PKD1 or PKD2. PKD1 is
Figure 1.1: T2-weighted images of kidneys in ADPKD patients.
located on chromosome 16p13.3 and encodes polycystin 1 (PC-1), an integral
membrane protein with 11 transmembrane domains and a large extracellular
structure involved in cell-cell and/or cell-matrix interactions; PKD2 is located
on chromosome 4q21 and encodes polycystin 2 (PC-2), a transmembrane gly-
coprotein that functions as a nonselective cation channel [5, 6]. Mutation in
PKD1 gene causes type 1 ADPKD while mutation in PKD2 gene causes type
2 ADPKD. Type 1 ADPKD is the most common and accounts for nearly 85%
of cases. It has been noticed that the disease is more severe in patients with
PKD1 genotype and that end-stage renal disease develop earlier then in those
with PKD2 genotype. ADPKD has a slow lifetime progression and generally
patients remain asymptomatic for decades. 50% of the offspring inherite the mu-
tated gene so, in case of absence of family history, early diagnosis of ADPKD is
difficult. These fluid-filled cysts, while expanding, compress the kidney vascula-
ture. The progression rate of the disease is related to the position and number
of cysts. The most common extrarenal manifestation is polycystic liver disease
which is characterized by the development and growth of hepatic cysts leading
to liver enlargement. Typical symptoms of polycystic liver disease are related
to the liver mass and include dyspnoea, early satiety, gastro- oesophageal re-
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flux, and mechanical low-back pain. Other ADPKD’s sympthoms can include
hypertension, intracranial aneurysms, mitral valve prolapse and acute pain that
can be associated with renal haemorrhage, passage of stones, and urinary tract
infections [7].
Clinical symptoms usually occur by late middle age and do not provide good
indications on the progression of the disease. Furthermore, in the early stage of
the disease there is a period of latency in which the renal function, quantified as
glomerular filtration rate (GFR) is stable. This is due to the ability of unaffected
nephrons for compensating the loss nephrons (figure 1.2) [1]. When most of
Figure 1.2: The natural history of autosomal dominant polycystic kidney dis-
ease as depicted by renal function decline as well as the onset of physical and
psychological symptoms [1].
parenchyma turns in cystic and fibrotic tissue, the compensation mechanism
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is overwhelmed, GFR decreases substantially and the remaining parenchyma
is irreversibly damaged. This has been noticed to happen when at least 50%
of functioning parenchyma has been destroyed [8]. For these reasons, GFR,
which is the conventional biomarker to evaluate renal function, is not considered
useful in PKD evaluation. In order to identify markers of disease progression
the Consortium for Radiologic Imaging Studies in Polycystic Kidney Disease
(CRISP) was created. According to CRISP, TKV provides an accurate measure
of cyst burden and its variation during time is correlated with the decline of
GFR. Changes in TKV can be detected in the early stages of the disease so
it represents an important biomarker for prognosis as for evaluation of disease
progression. Nowadays, cystic burden, measured as total kidney volume, is being
established as the best available biomarker of disease progression [9]. Recent
prospective longitudinal studies have shown as height-adjusted TKV (htTKV)
value of 600 cc/m in adults predicts the onset of renal insufficiency within 8
years. Monitoring cyst espansion has become important to predict outcome or
complication of possible therapies; therefore renal imaging plays a crucial role
in the diagnosis as in the assessment of the progression of ADPKD.
1.2 Clinical trials and outcomes
Since the identification of PKD1 and PKD2 genes as responsible for ADPKD,
a lot of different studies have been undertaken providing new insight into the
disease. These studies aim to explore novel therapeutic targets like high dose
niacinamide, tyrosine kinase inhibitors and others [10]. The main limitation
of these clinical studies is the need of long follow-up, because of the slow pro-
gression of the disease and the lack of early sensitive biomarkers. In the next
sections will be presented the most recent clinical trials grouped by therapeutic
targets.
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Blood pressure and the renin-angiotensin system
Hypertension occurs in a majority of the patients while their renal function is
still preserved. It is associated to kidney enlargement [11] and contributes to
patient morbidity and mortality. It is believed that cyst expansion lead to com-
pression of the vascular tree causing renal ischaemia and activation of the renin-
angiotensin aldosterone system (RAAS) [12] and so inhibitors of RAAS such as
angiotensin-converting enzyme (ACE), can affect the progression of the disease.
In the Halt Progression of Polycystic Kidney Disease (HALT-PKD) clinical
trial, ACE inhibition (ACEI) was compared with combined ACEI/angiotensin
receptor blockade. Data from HALT-PKD showed that low blow pressure tar-
get (<110/75 mm Hg) is associated with a slower enlargement of the kidneys
but there was no statistical significance between the estimated GFR and the
treatment.
Vasopressin V2 receptor antagonists
Cyclic adenosine-monophosphate (cAMP) activate cyst formation enabling chloride-
driven fluid secretion. Studies on animal models demonstrated the effectiveness
of vasopressin V2 receptor (V2R) antagonists in the treatment of ADPKD in an-
imal models [13]. Based on these results tolvaptan, a V2R antagonist was tested
in ADPKD. The Tolvaptan Efficacy and Safety in Management of Autosomal
Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial [14]
was a 3-year prospective, randomized, double-blinded, controlled clinical trial
in adult patients (18-50 years of age) with ADPKD, an estimated creatinine
clearance >60 ml/min, a total kidney volume >750 ml and preserved GFR.
The administration of tolvaptan in the total TEMPO 3:4 trial population re-
duced the rate of change kidney volume and was associated with a slower decline
of kidney function over 36 months compared to patients on placebo. Adverse
events, including hirst, polyuria, nocturia, and polydipsia, were documented
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during the treatment and because of this 8% of patients in the treatment group
discontinued the trial drug.
Somatostatin analogs
Somatostatin is a peptide inhibitory hormone able to inhibit the generation of
intracellular cAMP. The ALADIN trial (A Long-Acting somatostatin on DIs-
ease progression in Nephropathy due to ADPKD) [15] was a prospective, ran-
domised, single-blind, placebo-controlled trial in patients with ADPKD and
estimated GFR between 40-15 ml/min/1.73m2. In this pilot study the poten-
tial of somatostatin analogue octreotide in inhibiting the growth of renal cysts
was evaluated. The administration of octreotide showed a reduction in the in-
crement of TKV and a slowdown in GFR decline, suggesting that somatostatin
analogues can be considered a viable option for long-term treatment of ADPKD.
Main limitation of this study was the small sample.
Other trials investigating the potential of somatostatin analogs are ALADIN 2
recruiting 98 patients and the DIPAK 1, involving 300 patients.
Mammalian target of rapamycin (mTOR) inhibitors
Studies on animal models have shown that a drug treatment based on sirolimus,
a mammalian target of rapamycin (mTOR) inhibitor can retard cyst expansion.
The results of clinical trials in ADPKD patients [16, 17, 18] have been discour-
aging. Considering the importance of mTOR activation in the pathogenesis of
ADPKD the lack of clinical efficacy is probably due to the inability to admin-
ister sufficient dosage to achieve biological efficacy [10]. A possible approach to
overcome mTOR inhibitor systemic toxicity, while achieving a sufficient level to
inhibit mTOR activity in the kidney, could be to target the drug specifically to
the kidney [19].
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1.3 The role of imaging for the diagnosis of ADPKD
Given the hereditary nature of the disease, genetic testing can be used for
ADPKD diagnosis but, due to genetic and allelic heterogeneity, large multi-
exon genes, duplication of PKD1, and a high level of unclassified variants it is
technical challenging [20]. Because of the high costs and low accuracy (about
80%), the use of genetic testing for diagnosis of ADPKD is limited to the eval-
uation of kidney donors or in presence of a negative family history.
Diagnosis of ADPKD is tipically based on imaging criteria according to age,
family history and number of cysts in individuals. The following diagnostic
criteria are used for patients suspected with PKD according to their age [21]:
• For patients aged 15-39 years the presence of 3 or more unilateral or bi-
lateral cysts has a sensitivity of 0.7 and specificity of 1, positive predictive
value of 1 and negative predictive value of 0.7.
• For patients aged 40-59 the presence of 2 or more unilateral or bilateral
cysts has a sensitivity of 1, specificity of 0.9, positive predictive value of
0.9 and negative predictive value of 1.
• For patients aged 60 years or older the presence of 4 or more cysts in each
kidney has a sensitivity of 1 and specificity of 1.
Cysts can be detected using ultrasonography (US), magnetic resonance imag-
ing (MRI) and computed tomography (CT). MRI and CT can provide high
resolution images and so have an high sensitivity in detecting even small renal
cysts (less than one centimeter in diameter). Due to low cost and no radiation
exposure, ultrasound is the modality of choice while MRI is generally used when
US is inconclusive.
Ravine’s criteria [22] (table 1.1) hass good sensitivity in diagnosis of type 1
ADPKD but showed lower performance in detecting type 2 ADPKD. A unified
criteria that allow to overcome this limitation is the one presented by Pei [23]
(table 1.2) that shows good sensitivity for both PKD1 and PKD2.
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Number of cysts
Age (years) Positive family history Negative family history
<30 At least 2 in one or both kidneys At least 5
30-59 At least 2 in each kidney At least 5
>60 At least 3 in each kidney At least 58
Table 1.1: Ravine’s criteria for type 1 ADPKD diagnosis.
Age (years) Number of cysts
15-39 Total >3, uni- or bilateral
40-59 Total >4, at least 2 within each kidney
>60 Total >8, at least 4 within each kidney
Table 1.2: Pei’s criteria for ultrasonographic diagnosis of ADPKD in patients
with positive family history.
Furthermore, presence of liver cysts is tipically observed in 85% of patients
by the age of 30 and this information could be used for diagnosis validation
especially in absence of a positive family history of ADPKD [24].
In (table 1.3) are summerized the ultrasound diagnostic results for adults
with ADPKD obtained with Ravine’s and Pei’s criteria [25].
1.4 The role of imaging in assessing ADPKD
progression
Different studies have shown a link between the progression of cyst growth and
renal failure in PKD. It is belived that monitoring cyst volume is helpful for
assessing disease progression and evaluating the efficacy of new therapies. Ul-
trasonography is wildly used for diagnosis of ADPKD but not for the assessment
of disease progression because it is highly operator dependent and it has low
20




≥ 1 cyst 96.2
≥ 2 cysts 96.2
≥ 2 cyst in one kidney,
≥ 1 cyst in the other
88.5
≥ 2, bilateral 84.6
≥ 4 bilateral 80.8
30–59 PKD1
≥ 1 cyst 100
≥ 2 cysts 100
≥ 2 cyst in one kidney,
≥ 1 cyst in the other
100
≥ 2, bilateral 100
≥ 4 bilateral 100
Adult unified criteria































Table 1.3: Ultrasound diagnostic results for adults with ADPKD obtained
with Ravine’s and Pei’s criteria
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resolution. The use of US is generally limited to image kidneys of small size.
Estimation of total kidney volume from US is generally obtained approximating
the kidney shape with an ellipsoid, using the following formula:
pi/6 · length · width · depth
where length, width and depth correspond to the principal axes and are man-
ually selected by the operator. Different factors can influence accuracy and
reproducibility of this estimates such as the inter operator-variability in detect-
ing the different axes of the ellipsoid, respiratory motion and the non-uniform
distribution of cysts that makes the morphology of an ADPKD kidney irregular
and far to be considered comparable with an ellipsoid. As a result of these
limitations, kidney volume from US obtained applying the ellipsoid formula is
underestimated. A study [26] was conducted to evaluate the accuracy of ellip-
soid formula in calculating the renal volume from US, comparing the results
with the ones obtained using MRI images. The same underestimation occurred
applying the formula to MRI images exhibiting the intrinsic inadequacy of this
approach. Ultrasounds usually are not taken into consideration for the assess-
ment of disease progression. The first study based on renal volume estimation
on ADPKD patients was performed using CT images [27]. Other studies pro-
posed the use of CT for TKV computation suggesting the use of electron-beam
or spiral CT in order to increase accuracy in the measurement [28, 29, 30, 31].
Advantages in using CT images for renal volumetric analysis are related to
the high resolution of the images that can be also acquired faster than MRI.
Disadvantages of CT include ionizing radiation and exposure and, mainly due
to the low level of contrast of these images, the use of nephrotoxic contrast
agents. Because of these limitations the use of CT in the assessment of disease
progression is actually limited. Nowadays MRI is the modality of choice for
the assessment of ADPKD progression. The CRISP conducted a prospective,
longitudinal study of renal volume progression in patients with ADPKD using
T1-weighted and T2-weighted MRI images. Evidence of this study was that
kidney volume is the best biomarker for evaluating the rapid progression of the
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disease and that MRI is the best technique for its computation. Furthermore it
has to be considered that, being the renal enlargement due to cyst expansion,
kidney volume is a surrogate biomarker for cyst volume. Because of the high
image quality, MRI is the only technique that can allow cyst volume estimation
and cyst counting. Different methods have been proposed over the years for
kidney and cyst volume estimation in CT and MRI. They will be described in
the next chapters.
1.5 Aims of this Thesis
This thesis is focused on the development of new segmentation models for the
characterization of ADPKD patient through accurate estimation of renal and
cyst volumes. In addition, diffusion imaging analysis is proposed for an early




ADPKD patients from MRI
Magnetic resonance is usually the imaging technique of choice in the evaluation
of the progression of ADPKD. It is able to image the kidney with an high level
of detail and high resolution and because of this it can facilitate the evaluation
of the renal volume but also of cyst volume. Furthermore the CRISP defined
MRI as the best technique for the volumetric evaluation for the assessment of the
rapid progression of the disease. In this chapter are reviewed the recent methods
that have been proposed in scientific literature for the volumetric analysis in
ADPKD patients from MRI images and will be presented novel approaches for
kidney and cyst volume computation.
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2.1 State-of-the-art methods
2.1.1 Kidney volume estimation
Mid-slice method
This method refers to the one proposed by Bae [32] for the estimation of kidney
volume and may be applicable to MR and CT images. First the mid-slice,
defined as the slice positioned in the middle of the image set, is selected. Then,
the renal area obtained with manual contouring of this slice is multiplied for
the number of slices and for a correction factor of 0.637 for the right kidney
and 0.624 for the left kidney. The results obtained by this method have shown
good correlation with volumes obtained with manual contouring and better
performance in comparison with ellipsoid method. The main limitation is the
assumption that a single slice can be representative of the whole kidney. Given
the high heterogeneity of polycystic kidneys, this method results to be not
suitable for an accurate estimation of kidney volume.
Kidney segmentation during follow-up
In 2015 Kline proposed an automatic method for TKV computation on follow-up
MRI [33]. It is based on the registration of the volume detected using stereology
on the baseline scan with the follow up scan. The registration is initialized using
the image position information obtained from the DICOM header and optimized
using inverse warp. The final result is refined using a geodesic active contour
model. Good agreement was obtained with manual segmentation results. This
method is an important instrument for an accurate estimation of TKV and can
require only few minutes for the computation despite 30-40 minutes required for
manual tracing or stereology approach. Nonetheless, since the aim is to compute
TKV from follow-up, baseline kidneys still have to be manually segmented.
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Kidney segmentation with a priori knowledge
In this study [34], the segmentation of the kidneys is achieved using a level
set approach. Constraints during the level set evolution are a spatial prior
probability map (SPPM) and a propagated shape constraint (PSC). SPPM is
obtained using the manual segmentation of the kidneys from a training set of 30
patients. Performance of this fully automated method are good when compared
to manual segmentation. Nevertheless, a priori knowledge is needed and, as
stated by the author, this method depends strongly from the training set.
2.1.2 Cyst volume estimation
Region-based thresholding
The first method for cyst segmentation was proposed in 2000 by Bae [35].
In each slice an expert radiologist chooses the threshold that allows to better
distinguish beetween cysts and parenchyma. Voxel counting is then used for
TCV estimation.
Mid-slice method
This method use the same approach used for TKV estimation [32]. First, the
mid-slice, defined as the slice positioned in the middle of the image set, is
selected. Then, cysts are manually detected and cyst mid-slice area is calculated
by pixel count. The cyst volume is obtained multipling the cyst mid-slice area
for the number of slices and using a correction coefficient of 0.637 and 0.608
for right and left kidney respectively. As for TKV estimation, the accuracy is
affected by how much the mid-slice is representative of the whole kidney.
Shape-detection method
The different steps involved in this method [36] include the use of:
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• rough segmentation of the original image through clustering ;
• filtered version of the original image for edge enhancement;
• shape detection level-set to identify a seed point of each cyst in combina-
tion with morphological operators;
• morphologic watershed algorithm.
The application of this method is limited to patients with relatively mild to
moderate ADPKD as stated in [36], and it is exceedingly complex as stated in
an another work from the same group [37].
Euclidean distance map method
To overcome the limitations of the previously presented method [36], the same
group proposed a slightly different approach [37].
The workflow of this algorithm includes:
• automatic or manual selection of a threshold;
• connected components analysis to label the cyst regions;
• the construction of an Euclidean distance map;
• watershed segmentation.
2.2 TKV from MRI
CRISP studies evidenced the correlation between renal volume increment and
renal function loss and considered MRI as the best tecnique for the computation
of TKV and suggested the use of coronal acquisitions.
In a previous work [38] a fast and nearly-automated technique for kidney seg-
mentation was developed. The method was applied to axial images and showed
to be able to provide accurate estimation of renal volumes from MRI data. It
was tested and validated on patients with ADPKD and normal renal function.
27
CRISP guidelines recommend the use of coronal images for TKV and TCV
measurement. Furthermore, since axial and coronal acquisitions differ from the
numbers of acquired planes and resolution, the derived volumes computed ap-
plying the disk method to these scans could lead to different estimates.
The mentioned method [38] was applied to images from the coronal view [39].
The aim was to evaluate the differences, if any, between kidney volumes ob-
tained from axial and coronal acquisitions and to compare this approach with
the one proposed by the CRISP in [32], in which TKV is based on a limited
number of manual area measurements.
2.2.1 Materials and methods
Thirty patients (23 patients with normal renal function and 7 patients with
chronic kidney disease) underwent the MRI study. In all patients ADPKD
had been previously diagnosed with echographic investigation and based on
Ravine’s criteria [22]. MRI data were acquired using a 1.5T scanner (Intera
Achieva, Philips Medical System). The imaging protocol included unenhanced
sequences only. T2-weighted turbo-spin-echo sequences with selective fat sup-
pression (SPIR) respiratory triggered were used to acquire axial images. The
kidneys were also imaged posteroanterior in the coronal plane using spectral adi-
abatic inversion recovery with single shot fast spin echo (SPAIR-SSFSE) with
fat saturation. MRI acquisition parameters are presented in table 2.1.
Acquisition parameters Axial Coronal
Spatial resolution (mm) 1.30 x 1.30 to 1.58 x 1.58 0.98 x 0.98
Field of view (cm) 30 to 35 30 to 35
Slice thickness (mm) 5 mm 5 mm
Table 2.1: MRI acquisition parameters
The proposed software was developed to detect kidney contours in both
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coronal and axial MR acquisition. The following procedure was applied to both
left and right kidneys as shown in figure 2.1
• one point manual selection in the central slice of a volume (a);
• rough segmentation based on Otsu method and region-growing (b);
• morphological operation and curvature motion for final segmentation (c).
Figure 2.1: Description of the segmentation procedure (from left to right):
manual selection of two points in the right and left kidneys (red stars); kidney
areas obtained applying a threshold segmentation; kidney contours obtained
applying a region growing algorithm and refined by curvature motion.
Starting from the mid-slice, this procedure is iterated forward and backward
for each slice in the volume and the seed point automatically recalculated in
each plane. Non-kidney structures such as liver or spleen are automatically
excluded. In particular the software operates a double check on the left kidney
to exclude the spleen. This step is obtained by looking for homogeneous areas
in the upper side of the left kidney and comparing the left kidney area of the
current slice with the area of the previous one. In case of a larger area and
if wide areas of homogeneity are detected, a seed is automatically positioned
in the homogeneous area and the result of the application of a region growing
algorithm is subtracted to the previous detection (figure 2.2).
For each slice, the kidney area is calculated by counting the number of pixels
inside the detected region and considering the data resolution in the acquired
plane. Left and right kidney volumes were obtained by summing the products
of the corresponding area measurements and the spacing between slices. The
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Figure 2.2: Description of the spleen exclusion from segmentation: a. Segmen-
tation result (red contour) and automatically positioned seed (red stars); b.
Result obtained applying a region growing based segmentation in the spleen
region; c. Final kidney segmentation
software proposed above works indifferently on images from axial and coronal
MRI acquisitions to obtain kidney volumes (KVax and KVcor, respectively).
Left and right kidney volumes were also estimated by manual tracing of two
independent experts (KVmt) and applying the method described in [32] (KVap).
The coronal MR mid-slices of the right and left kidney were manually selected.
Mid-slice was defined as the slice whose image number corresponded to a half of
the sum of the first and last slice image numbers in the image set. The volume
was computed as the product of the mid-slice kidney area and the number of
slices covering the kidney and a multiplier derived from the linear best fit model
computed for the comparison, as indicated in [32].
2.2.2 Statistical analysis and results
For each patient, kidney volumes obtained from nearly-automated analysis from
axial and coronal acquisitions were compared. In addition, the latter ones were
also compared with the volume estimates derived by manually tracing of kid-
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ney contours and as described in [32]. Comparison was performed using linear
regression and Bland-Altman analyses. Paired t-test was applied to verify the
significance of the bias.
In addition, to assess the effects of the placement of a single seed point inside
the renal cavities kidney (which was the only user input in the analysis), the
repeatability of volume measurements was tested in fifteen randomly selected
patients in both acquisitions. One observer repeated the analysis twice, select-
ing two different seed points to compute intra- observer variability. A second
observer analyzed the MR data to compute inter-observer variability. The re-
peatability analysis was also performed to estimate inter-observer variability
between volumes derived by manual tracing. Variability measurements were
computed as the ratio between the absolute difference between the two volume
measurements and their mean value and expressed in percent of their mean.
Two examples of the detected contours in two patients from coronal and
axial acquisitions are shown in figure 2.3.
Examples of the segmentation result in one slice for one patient characterized
by few cysts and small kidneys and one patient with several cysts and huge
kidneys are shown in figure 2.4.
Median value for KVax estimated in 30 patients was equal to 1298 ml (668 ÷
1973 ml); KVcor resulted in 1298 ml (693-2029 ml) (NS). The same comparison
was performed considering right and left kidney volumes separately. Median
value for right KVax was equal to 673 ml (321-977 ml) and median value for
right KVcor resulted in 651 ml (337-972 ml) (NS). Median left KVax was equal
to 614 ml (347-850 ml) and median left KVcor resulted in 617 ml (350- 890 ml)
(NS). These ranges reflect the wide variability of the analyzed ADPKD patients.
Linear regression analysis between left KVax and left KVcor (figure 2.5,
left top panel, black dots) resulted in an excellent correlation coefficient and
regression slope near to 1 (left: KVcor=1.01KVax-2.00; r2=0.996).
Similar results were found for right KV (figure 2.5, right top panel, black
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Figure 2.3: Detected contours in two different patients from coronal and axial
acquisitions
dots; right: KVcor=1.00KVax+5.30; r2=0.996). Bland-Altman analysis (fig-
ure 2.5, bottom panels, black dots) showed a negligible bias between the volume
measurements from axial and coronal analysis (bias: -6.7 ml and -5 ml corre-
sponding to -0.9% and -0.7% for left and right KV, respectively). The 95% limits
of agreement were relatively narrow (SD: 35.1 ml and 31.5 ml for left and right
KV, respectively), providing additional support to the tight agreement between
the volume quantification based on axial and coronal acquisitions. Overall, the
mean percentage error for the volume assessment in the left and right kidneys
resulted in -0.9±6.5% and -0.7±5.5% respectively. In addition, mean absolute
percentage error was 5.1±4.0% and 4.0±3.7%.
Linear regression and Bland-Altman analyses (figure 2.6, black dots) between
the TKVax and TKVcor confirmed the excellent results obtained for single kid-
ney estimates (y=1.01x-0.78; r2=0.997; bias: -11.7 ml corresponding to -1.5%;
SD: 54.3 ml; mean percentage error: - 0.8±4.9%; mean absolute percentage er-
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Figure 2.4: Detected contours for one patient with several cysts and huge kid-
neys (left panels) and one patient characterized by few cysts and small kid-
neys (right panel).
ror: 4.0±2.8%). Paired t-test between volumes computed analyzing coronal and
axial images showed non- significant differences for left, right and total kidney
volumes (p¿0.2). Results of the comparison between volumes obtained applying
the method proposed in [32] and the nearly-automated method to coronal ac-
quisitions are shown in figure 2.5 (gray dots) for left and right kidney volumes
and in figure 2.6 (gray dots) for total kidney volumes.
Quantitative results are summarized in table 2.2.
On a subset of 15 patients, intra- and inter-observer variability in right
and left kidney volume measurements obtained applying the nearly-automated
method on coronal and axial acquisitions, were 1.8±1.5%, 2.3±1.9%, 1.8±3.1%,
2.5±2.9% and 2.1±2.5%, 1.9±2.3%, 1.8±3.2%, 2.6±4.3%, respectively (figure 2.7).
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Figure 2.5: Linear regression and Bland-Altman analysis of left (left panels)
and right (right panels) kidney volumes.
regression line r bias (ml, (%)) SD(ml) %error |%error|
left KVap vs KVcor y=1.00x+49.37 0.994 -50 (-6.8) 60.8 -10.1±14.1 13.7±10.5
right KVap vs KVcor y=0.95x+37.54 0.989 -3.7 (-0.5) 81.1 -2.5±10.6 8.7±6.5
total KVap vs KVcor y=0.98x+75.91 0.995 -53.7 (-7.3) 108.1 -5.8±10.8 9.8±7.3
Table 2.2: TRV results obtained from the analysis of coronal acquisition ap-
plying our highly-automated method (KVcor) and the method based on geo-
metric approximations proposed in (KVap).
On note, inter-observer variability computed between the two experts who man-
ually traced the kidney contours on coronal acquisition resulted in 2.6±1.5% and
2.3±1.4% for right and left kidney respectively.
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Figure 2.6: Linear regression and Bland-Altman analysis of total kidney vol-
umes.
2.2.3 Discussions
The results showed the method is not tight up to a specific imaging protocol
and works when using the CRISP-recommended acquisition protocol and the
routine abdominal protocol; therefore, the tool could be valuable in different
clinical scenarios when kidneys are imaged for different clinical reasons and the
need for renal volume computation is after the fact. The advantage of such
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Figure 2.7: Intra- and inter-observer variability in right and left kidney vol-
ume measurements on coronal and axial acquisitions
approach relies in the ability to include in our population also patients with
huge kidneys. The comparison with kidney volume measurements evaluated
using geometric modeling proposed by CRISP [32] showed not negligible bias
and large limits of agreement. Both methods perform well on wide range of
kidney size and with mild and moderate cystic burden as well as in those in which
parenchyma is largely replaced by cysts. However, when kidney shape is not
regular and the presence of exophytic cysts or regional morphological variations
deform renal contours, volume measurements result inaccurate if evaluated using
geometric modeling [32], leading to the large limits of agreement. Two examples
in two patients are reported in figure 2.8. In these two cases, the presence of
exophytic cysts, not visible in the central plane of the coronal acquisition, result
in not negligible errors in left kidney volume estimation applying the geometric
modeling based approach. No manual tracing of kidney contours is required for
the nearly-automated method and the only manual intervention is the selection
of two points inside a single slice of both kidneys whose position was proven
not to significantly affect volume estimates by the repeatability analysis. The
seeds selected by the user are just an indication of the region to detect and
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their position is optimized automatically studying the gray level intensities in a
region of interest around the selected points; therefore their initial positions do
not affect the final quantitative results. These results were confirmed by intra
and inter-observer variability values that resulted very small and negligible for
both acquisition views, minor than those computed for manual tracing and those
reported in literature applying manual tracing or stereology method [40].
In figure 2.9 is presented the interface developed for kidney segmentation based
on this method.
Figure 2.8: Example of the exophytic cysts (indicate by the arrows) erro-
neously excluded by the segmentation model.
2.3 Patient classification based on TKV
Total kidney volume variation is extensively used in clinical practice to evaluate
disease progression and for monitoring treatment efficacy [41]. Height-adjusted
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Figure 2.9: User interface for ADPK segmentation
TKV (HtTKV) in combination with age has been also proposed for patient clas-
sification which is important for selecting patients for clinical trials [42].
As already reported, different methods have been proposed for computation
of TKV in ADPKD patients from MRI. Some of them rely on geometric ap-
proximations [32], [42]; others are highly automated [38], [39] requiring a single
seed point selection in one mid MR slice to obtain the 3D kidney surfaces and
still others [33] and [34], use fully automated approaches. [33] was exclusively
proposed to monitor disease progression starting from patient kidney surfaces
obtained by manual contouring during first visit; while [34] was based on spatial
probability density maps and regional mapping with total variation regulariza-
tion and propagated shape constraints.
In the next section a study conducted to perform a quantitative comparison
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of the performance of the available methods for TKV computation is described.
Two methods based on geometric assumptions (mid-slice, ellipsoid) and a third
one on true contour detection were tested on forty ADPKD patients at differ-
ent disease stage using MRI. Ellipsoid method was also tested using ultrasound
images in a subset of fourteen patients. Their performance was compared ver-
sus TKVs derived from reference manual segmentation of MR images. Aim of
this study is to evaluate if differences in TKV can lead to different prognostic
classification [42].
2.3.1 Materials and methods
Forty patients were enrolled in this study. In all the patients ADPKD was
diagnosed based on the Ultrasonographic Unified Criteria [23] and MR images
were acquired following the acquisition protocol described in [43]. In a subset
of fourteen patients ultrasound images were available. Patients characteristics
are reported in table 2.3.
TKV was estimated using the ellipsoid method [42], the mid-slice approach [32]
and the highly-automated method described in the previous section.
Characteristics Value
Number of patients 40
Sex (M/F)(%) 56,4/43,6
Age at visit (years) Mean [range] 44 [21-66]
Creatinine (mg/dl) Mean [range] 1,37 [0,6-2,13]
GFR (CKD-EPI ml/min/1.73 m2) Mean [range] 73,8 [32-131]
Number of patients treated with one anti-hypertensive drug 8
Number of patients treated with two anti-hypertensive drugs 4
Number of patients treated with at least 3 anti-hypertensive drugs 5
Table 2.3: Patients characteristics.
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2.3.2 Statistical analysis and results
To evaluate the agreement between TKVs computed applying the reference
technique, based on manual segmentation of MR images, and the different ap-
proaches, regression and Bland-Altman analyses were performed. Intra-class
correlation coefficients (ICC) and absolute errors were also computed for each
technique. Dice coefficient was computed for the methods in which kidney sur-
faces were available. In 20 patients randomly selected, kidney volumes from
MRI were computed twice by two reviewers, blinded to their previous results.
Based on computed TKVs, patient classification was assessed [42] and results
were compared with classification obtained using TKV from manual tracing.






















































Table 2.4: AUTO = highly-automated method, EL = ellipsoid method, IQR
= interquartile ranges (25%÷75%), KV = kidney volume, MS = mid-slice
method, *p<0.05 vs reference value by manual tracing, **p<0.01 vs reference
value by manual tracing.
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Kidney volume ICC 95 % CI [min ÷ max]
KVEL
(n=40)
Right 0.977 (p<0.001) 0.956 ÷ 0.988
Left 0.977 (p<0.001) 0.957 ÷ 0.988
Total 0.983 (p<0001) 0.967 ÷ 0.991
KVMS
(n=40)
Right 0.984 (p<0.001) 0.970 ÷ 0.992
Left 0.987 (p<0.001) 0.975 ÷ 0.993
Total 0.992 (p<0.001) 0.985 ÷ 0.996
KVAUTO
(n=40)
Right 0.999 (p<0.001) 0.998 ÷ 0.999
Left 0.997 (p<0.001) 0.995 ÷ 0.999
Total 0.999 (p<0.001) 0.997 ÷ 0.999
KVECHO
(n=40)
Right 0.862 (p<0.001) 0.635 ÷ 0.953
Left 0.864 (p<0.001) 0.550 ÷ 0.953
Total 0.843 (p<0.001) 0.592 ÷ 0.946
Table 2.5: 95% CI = 95% confidence intervals, ICC = Intra-class correlation
coefficients, KVAUTO = kidney volume by the highly-automated method,
KVecho= kidney volume by echography, KVEL = kidney volume by the el-
lipsoid method, KVMS = kidney volume by the mid-slice method.
Linear regression (figure 2.10, left panels) and Bland-Altman (figure 2.10,
right panels) analyses between kidney volumes estimates obtained applying the
three approaches based on MRI (MS, EL and AUTO) and echography versus
reference kidney volumes by manual tracing are shown in figure 2.10 for right,
left and total kidney volume respectively. The intra-class correlation coefficients
for TKV are reported in table 2.5.
We found a mean Dice coefficient of 0.98±0.02 and 0.97±0.02 for right and
left kidney respectively applying the highly automated method. Patient classifi-
cation according to the Mayo Clinic calculator [3] showed the following misclas-
sification: 5/40 (13%), 4/40 (10%), 1/40 (2.5%) using TKVs obtained applying
the ellipsoid, the mid-slice and the highly automated method, respectively. Im-
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portantly, in 14 patients in which echographic quantification was available, only
3 patients (21%) were correctly classified; in general, US-based classification
resulted in the assignment of the patient to a class associated to a lower kidney
growth rate.
Figure 2.10: Linear regression (left panels) and Bland-Altman analysis (right
panels) for right (top panels), left (mid panels) and both kidneys (bottom
panels) volumes applying the highly-automated (AUTO, red squares), ellip-
soid (EL, light blue diamonds) and mid-slice (MS, green triangles) methods




Different approaches for TKV computation were compared in the same group
of ADPKD patients at different disease stage characterized by a wide renal
volume range. The MRI-based methods resulted in excellent correlation coeffi-
cients and ICCs. However, Bland- Altman analysis showed underestimation of
different magnitude for the three techniques. Limits of agreement were highly
dependent from the applied method, showing the best agreement for the highly
automated technique (<5%); they were large for the EL method, resulting in
confidence intervals larger than 10%. Mean percentage errors confirmed these
results showing errors <1% for the highly automated technique. Importantly
both geometrical-based approaches show an increased volume underestimation
for both kidney volumes when kidney size increases. In addition, variability
analysis results exhibit that ellipsoid and mid-slice methods are highly operator-
dependent showing statistically different TKV estimates for both intra and inter-
observer variability. Overall, the best performance was obtained applying the
highly automated method. The results of this comparison are in line with the
ones previously presented [42, 39, 32]. Slight differences were found for variabil-
ity analysis that could be explained by considering the population selected for
this analysis is characterized by huge kidneys. In a previous study [44] sono-
graphic assessment of TKV by applying the ellipsoid method was compared
versus TKV derived from MRI. Results showed inaccurate ultrasound-based
TKV estimates and, differently from what we found, sonographic volumes were
greater than MRI-based TKV. However, authors state renal volume was exag-
gerated in the aggregate, but volume was also undermeasured in many kidneys.
The error was not related to kidney size or body habitus, suggesting that is
not caused by patient-specific factors, but much of the variability was related
to the sonographers. In addition, in this study, T1-weighted MR images were
used to derive TKV by stereology. A direct quantitative comparison with the
method presented in [34] was not possible since specific algorithm was not avail-
able. The method in [34] was tested on a population of smaller kidneys (TKV
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range: 177÷2634, mean TKV: 885±570) and validated versus manual tracing.
Compared to the highly automated method, linear regression coefficient and
ICC were slightly minor (r=0.97, ICC=0.97). Importantly computed bias was
between 25 and 30 ml (about 3.5%) but limits of agreement were huge (57 ml
vs 266 ml and 290 ml) compared to the ones obtained by the highly automated
method. Dice coefficient was also slightly lower (0.88±0.08) in [34]. Regarding
classification, a correct patient clustering is crucial to select patients who are
appropriate for clinical trials or, more importantly, likely to benefit from an ef-
fective treatment. Differently from [45], our results showed techniques based on
geometric models, both from echography and MRI, are not suitable for an ac-
curate patient stratification based on renal volume. Previous study [26] already
showed poor accuracy and reproducibility of ultrasound for TKV assessment
using the ellipsoid formula; however the use of TKV from echography applying
geometric models has been recently proposed as a prognostic index in ADPKD
population [46]. In [46], simultaneous ultrasound and magnetic resonance imag-
ing were used to determine whether ultrasound and kidney length predict future
chronic kidney disease stage 3 over 8 year follow-up. Results showed they are
equivalent for this purpose. This comparison is beyond the aim of this technical
note in which kidney length was not considered and the focus was on volumetric
information. However our preliminary results show an extremely low accuracy
of kidney estimation obtained from echographic exam and echo-derived mea-
surements lead to inaccurate patient stratification in the majority of patients.
Our study suggests that ultrasound prognostic estimation should be used with
extreme caution, and final clinical validation of this approach would require fur-
ther confirmation from independent studies. To conclude, approaches based on
image processing techniques [39, 38, 34] which already proved to provide good
results and could be ready for clinical testing, should be taken into account
for kidney volume quantification and monitoring. Importantly, differently from
ellipsoid and mid-slice methods, these approaches make available a 3D model of
the kidneys that could be very useful for further analysis including cyst detec-
tion, cyst volume computation and automatic classification of renal morphology
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(e.g. class 1 versus class 2 kidneys [42]).
2.4 TCV from MRI
TKV is widely considered as the best prognostic biomarker for the assessment of
renal function failure. However, kidney enlargement in ADPKD patients is due
to cyst expansion. The mechanisms beyond the formation and the growth of
cysts are still unknown but the estimation of cyst volume is a critical parameter
for the evaluation of the progression of the disease. The prognostic value of TKV
as surrogate biomarker for TCV can fail in predicting change in renal function,
as, for example, in patients with few large cysts or in patients with renal atrophy
secondary to ischemia or urinary tract obstruction [47]. As already stated, a
correct classification of an ADPKD patient is important for the evaluation of
therapy efficacy as for the enrollement of patients in clinical trials. In this
section a novel approach for fully automated cyst segmentation is presented.
2.4.1 Materials and methods
Algorithm for TCV assessment was tested in five patients. For all patients
ADPKD diagnostic was based on the Ultrasonographic Unified Criteria [23]
and MR images were acquired following the acquisition protocol described in
[43]. Segmentation of the kidneys was obtained using the validated method
described in [39] and used to mask the original data.
For each image in the MR dataset, the following procedure was designed.






A 3-class fuzzy c-means clustering was applied to every single image in order
to distinguish cystic from parenchymal regions. Fuzzy clustering resulted in a
powerful unsupervised method for the analysis of this kind of data, allowing to
obtain quick estimation of TCV. Later on in the manuscript, the results of TCV
estimation will be presented and discussed. An example of the clustering result
is shown in figure 2.11
(a) Original image with kidney seg-
mentation mask
(b) Cyst detection by 3-class cluster-
ing
Figure 2.11: Result from the clustering of a segmented kidney
Seed detection
This clustering results in the detection of different regions that can be associated
to a single or multiple cysts. Only regions with an area bigger than twice the
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slice thickness are taken in consideration for this kind of analysis since the aim
is to distinguish every single cyst and estimate its volume. The iterative voting
approach used for the detection of single cysts is based on the consideration that
cyst expansion occurs radially without a preferential direction and can be mod-
elled by a sphere. In a more general scenario cyst expansion is conditioned by
the presence of other cysts resulting in an agglomerate. These regions, detected
by the clustering approach previously described, are convex and often radially
symetric.
In this section will be described the iterative radial voting approach [48] used
to locate the centroid of each cyst.
Let I(x, y) be the original image where (x, y) are the spatial coordinates of a
point in the image domain, ∇I(x, y) the image gradient, ‖∇I(x, y)‖ the mag-
nitude of the image gradient and α(x, y) := (cos(θ(x, y)), sin(θ(x, y))) be the
voting direction at each point of the image for some angle θ(x, y) that varies
with the image location and is the angle of the gradient direction respect to x
axis. Defining a subset of pixels S := {(x, y)|‖∇I(x, y)‖ > Γg} where Γg is the
gradient threshold and considering that in the binary mask resulting from the
clustering, the background pixels are set to zero, for each point (x, y) ∈ S the
voting direction can be defined as the negative gradient direction:
α(x, y) := − ∇I(x, y)‖∇I(x, y)‖ .
Being the centroid of a cyst far away from its boundary, in order to reduce
the number of calculations, for each point (x, y) ∈ S is defined a cone shape
voting area A(x, y; rmin, rmax,∆) dependent on the radial range rmin, rmax and
on the angular range ∆.
A(x, y; rmin, rmax,∆) := {(x ± r cosφ, y ± r sinφ) | rmin ≤ r ≤ rmax and
θ(x, y)−∆(x, y) ≤ φ ≤ θ(x, y) + ∆(x, y)}
In the center of the voting area is defined a 2D Gaussian kernel g(x, y, σ) as
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with variance σ2. The voting area so defined is illustrated in figure 2.12.
Figure 2.12: Cone shape voting area with Gaussian kernel positioned in its
center.
Each pixel of the object interface contributes to a vote image that has the
same size of the original image, is initialized to zero and defined as:
V (x, y; rmin, rmax,∆) =
∑
(u,v)∈A(x,y;rmin,rmax,∆)
{F (x, y)g(u, v, σ)}
where the feature image F (x, y) is the local external force at each pixel of
the original image. In this study, as external force, it has been choosen the
mean curvature k defined as:




In order to reduce the computational weight and so to increase efficiency,
differently by [49], here it has been used a single pass approach similarly to [48]
to locate the seeds for the next step. The centroids of the detected objects are
detected selecting the local maxima of the resulting voting image (V ).
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An example of the intermediate steps to achieve the detection of the centroid
on a synthetic image is shown in figure 2.13 (central panels).
Figure 2.13: Examples of the segmentation of touching objects on synthetic
images: test images (left panels); seed detection (central panels); result of seg-
mentation (right panels).
Cyst segmentation
The detected centroids are used as seeds for the segmentation of cysts that
has been obtained using a level set approach based on interactive model. The
mechanism involved in the interaction are a repulsion term for separating the
touching cysts and preventing the contours from overlapping and a competition
term for defining the boundaries and to determine the membership of each pixel.
Let be Ci(i = 1, ..., N) where N is the number of detected cysts (centroids) for
the considered clustered object. Each cysts is represented by its own level set
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energy function Ψi with Ci as the zero level set such as Ci = {(x, y)|Ψi(x, y) =
0}. In the multiphase level set approach each level set (Ψi) interacts with the
others through the repulsion and competion terms. The evolution of each curve
is obtained by the minimization of the energy function and can be expressed as
∂Ψi
∂t
= δ(Ψi){λo|I − ci|2 − λb|I − cb|2
N∏
j=1,j 6=i
H(Ψj) + . . .








where g is the edge indicator, H is the Heaviside function, δ the Dirac
function and λo, λb, µ are parameters of the equation.
Examples of the final segmentation through the multiphase level set ap-
proach of a synthetic image is shown in figure 2.13 (right panels).
Cyst counting
As previously mentioned, only regions with an area bigger than twice the slice
thickness underwent the based on the multiphase segmentation approach. Seed
detection is a crucial step and an erroneous in the detection of the centroid of
the regions can lead to over- or under- segmentation of the agglomerate of cysts.
The developed approach for cyst counting allows to detect the number of cysts
in the kidney using the position of the centroids of each segmented object.
The different 2D segmented objects are associated to a single 3D object (a cyst)
depending of the closeness of their centroids in the third dimension and the
percentage of overlap between them. The redundancy of these informations
along the third dimension allows also to overcome the limitation of the method
for seed detection.
50
2.4.2 Statistical analysis and results
An example of the result of the previosly described workflow on an agglomerate
of cysts is shown in figure 2.14. Two expert radiologist manually traced the
Figure 2.14: Intermediate steps of the segmentation algorithm: original image
(top left); agglomerate of cysts detected through clustering (top right); detec-
tion of cyst centroids (bottom left); result of the segmentation (bottom right).
cysts in both kidneys of each of the five patients providing two estimations of
the volume of the cysts. Cyst volume obtained from the automatic method was
compared with the mean of the two manual estimated cyst volumes. Comparison
was performed using linear regression and Bland-Altman analyses, figure 2.15.
Linear regression resulted in an excellent correlation coefficient and regression
slope near to 1 (y=1.00x-0.89; r=0.987).
Bland-Altman analysis showed a moderate bias (bias: -0.26 ml corresponding
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Figure 2.15: Linear regression and Bland-Altman analyses of TCV
to -0.30%).
The 95% limits of agreement resulted in 6.03 ml, mean percentage error was
-1.1 ± 5.1% and mean absolute percentage error was 4.5±2.3%.
Residual parenchyma percentage was computed using the estimated CV from



























1 239.65 78,58 93,34 85.96 ± 10.44 78.90 -8.22 67.08 32.92
2 365,47 48,92 53,53 51.22 ± 3.26 52.01 1.53 85.77 14.23
3 350.57 117,44 135,64 126.54 ± 12.87 121.96 -3.62 65.21 34.79
4 208.59 29,82 31,45 30.60 ± 1.15 30.03 -1.97 85.60 14.40
5 447.91 137,44 159,38 148,41 ± 15.51 160.07 7.86 64.26 35.74
Left
kidney
1 230.94 36,11 37,53 36.82 ± 1.00 34.91 -5.18 84.88 15.12
2 486.73 76,30 94,02 85.16 ± 12.53 86.87 2.00 82.15 17.85
3 377.68 165,77 180,48 173.13 ± 10.40 164.65 -4.89 56.40 43.60
4 179.83 14,17 12,22 13.19 ± 1.38 12.57 -4.72 93.01 6.99
5 454.8 114,63 131,79 123.21 ± 12.13 129.65 5.23 71.49 28.51
Table 2.6: TCV and parenchyma estimation. ME1: Manual estimation #1;
ME2: Manual estimation #2; AE: Automatic estimation;
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Cyst counting allowed to obtain the volume of each cyst and so to quantify
the contribution of each single cyst to the total cyst volume. In table 2.7 is shown
the volume of the five biggest cysts for each kidney that has been analyzed.
An example of the segmented cystic burden is shown in figure 2.16.
Figure 2.16: Example of the segmented cyst volume (green), right kidney, pa-
tient 3.



































































































































Table 2.7: Volume and TCV percentage of the five biggest cysts for each kid-
ney.
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Figure 2.17: 3D representation of the three biggest cysts (in volume descen-
dent order: red, green, blue) for left (left panels) and right (right panels) kid-
neys from patient 1 (top panels) to patient 5 (bottom panels).
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2.4.3 Discussions
Total kidney volume is the common biomarker for the assessment of the poly-
cystic disease. However TKV is computed in place of TCV since kidney en-
largerment is mainly due to cyst expansion. The results presented in this study
show as kidney with similar volume may have different residual parenchyma
percentage (e. g. right kidney patient 2 versus right kidney patient 3, table 2.6)
and so as TKV is not sufficient for assessing the progression of the disease.
Furthermore, it is interesting to note that in some cases the two biggest cysts
contribute to around half of TCV as shown in table 2.7 for right kidney of pa-
tient 3 and 4 and for left kidney of patient 3.
There are two phases of cystogenesis, an initial one gene-related and character-
ized by the development of cysts and a subsequent one, that is gene-independent
and characterized by cyst enlargement [50]. The higher severity of PKD1 in
comparison with PKD2 is due to number of cysts but not to the rate of cystic
growth. The method that has been presented in this section can be an important
instrument for the assessment of ADPKD progression as it provides quantita-
tive informations about the number of cysts but also their volume and position,
opening the possibility of new insight in the characterization of the ADPKD




ADPKD patients from CT
Despite the drawbacks related to the use of ionizing radiation, computed tomag-
raphy is wildly used in clinical practice because it allows to acquire images
faster than MRI and because of the widespread presence of CT scans in the
territory. Early studies based on volumetric analysis of polycystic kidneys were
performed on CT images but nowdays only few non manual approaches have
been proposed for the assessment of kidney volume in PKD and all of them are
based on contrast-enhanced CT images. In this chapter will be reviewed the
recent methods that have been proposed in literature for the volumetric analysis
in ADPKD patients from contrast-enhanced CT images and will be presented
novel approaches for the automated assessment of kidney and cyst volume in
ADPKD based on non-contrast-enhanced CT images.
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3.1 State-of-the-art methods
3.1.1 Kidney segmentation in CT
Multiclass Otsu’s thresholding approach
In a recent study [51], a new method for TKV/TCV estimation from CT was
proposed which differs from the manual approach.
Initially, kidneys are manually outlined by an expert radiology or, in case of
the absence of fat, segmented precisely to detect the area of interest. After this
initialization, the following workflow is used for this algorithm:
• generation of binary mask from outlined images;
• application of the binary mask to a filtered version of the original images
for image segmentation
• multiclass Otsu’s thresholding approach [52], to distinguish cystic and
parenchymal regions.
In the described method the authors used multislice CT in combination with
non-ionic contrast agent.
Random forests approach
In this study [53] random forests classifier was trained and tested on 55 contrast
enhanced CT images for kidney volume estimation. The different steps involved
in this procedure are:
• computation of the intensity weighted geodesic distance based on manual
segmentation of mid-slice;
• computation of a scalare feature value defining a box-feature based on
pixel intensities;
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• forest training and testing: different samples are selected 5 times so 44
samples are used for training and the remaining 11 for testing; training
is performed two times, with and without the geodesic distance volume
information.
3.2 Kidney and cyst volume estimation
The CRISP demonstrated that renal and cyst volume can be accurately and
reliably measured in ADPKD using MR imaging techniques [43]. MR acquisition
allows to overcome the limitation of CT such as the radiation exposure and the
administration of contrast medium that can be nephrotoxic in patients with
a decay in renal function [54]. In addition, MR images are able to provide
more soft tissue details when compared with CT and for all these reasons, MRI
is considered the best technique in clinical research. On the other hand, a CT
examination costs generally less, takes less time and have higher resolution than
MRI. Mainly because of the costs of an MRI system, small clinical centers, do
not have MR scanners and, in clinical practice, CT imaging in ADPKD is very
spread.
Despite the need and the continous progress made in the treatment of ADPKD
patients, no automatic methods have been proposed for the estimation of TKV
and TCV from CT images. As part of this Thesis, an automatic method for
renal volume analysis from CT images has been developed and will be presented
in the next sections. Importantly, no contrast medium was used during image
acquisition.
3.2.1 Materials and methods
Eight ADPKD patients were involved in this study. For all patients ADPKD di-
agnostic was based on the Ultrasonographic Unified Criteria [23]. Patient char-
acteristics are summerized in table 3.2. Images were acquired with a Siemens
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Characteristic Value
Number of patients 8
Sex (M/F) 4/4

















Table 3.1: Patient Characteristics.
Scope scan at the ”Spedali Civili” of Brescia, Italy. Acquisition protocol is
presented in table 3.1.
Tube voltage 130 KV
Tube current 37 mA
Matrix size 512x512 px
Pixel dimension 0.70 mm
Slice thickness 1.5 mm
Table 3.2: MRI protocol.
The proposed method has been developed for the detection of renal volume
in ADPKD patients from CT images acquired without the use of contrast-
medium (figure 3.1). It is fully-automated and the detection of kidneys contour
is operated simultaneously for right and left kidneys. The workflow includes the
pre-processing step, and the renal contour segmentation.
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Figure 3.1: Original computed tomography image.
Kidney detection
CT images are characterized by low contrast (figure 3.1) which means that
different tissues are represented with a few levels of gray and this is even more
true in case of avoiding contrast agents. Because of that, different steps are
involved for the localization of the kidneys.
Histogram analysis of the whole volume is performed in order to detect the
range of pixel intensity in which the organs are included which is usually the
last peak (figure 3.2, a). This allow to mask out bones and other structures
that are not of interest and to facilitate the following unsupervised clustering
which is based on pixel intensity information (figure 3.2, b). The whole volume
is so clustered in four classes and the two ones with lower mean pixel intensity
are taken in consideration. These classes tipically provide a rough segmentation
of kidneys and cysts in the acquired volume. The distribution of the number
of pixels associated to these classes in each slice of the acquired volume is then
analyzed (figure 3.2, c). By selecting the maximum of this distribution, it can
be identified the image plane with the the biggest kidney area which is generally
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positioned around the middle of the whole renal volume. Once identified the
the image plane the information provided by the clustering is used to detect the
kidneys (figure 3.2, d).
Figure 3.2: Description of the workflow for kidney detection on two different
patients. (a) Histogram analyses of the 3d volume and detection of the pixel
range; (b) Result of the 3d cluster in a single slice; (c) Number of pixel distri-
bution associated to lowest pixel intensity; (d) Detection of the kidneys.
Renal contour segmentation
The information about the position of the kidneys is used for the initialization of
a level set based segmentation. Before performing the segmentation the volume
has been filtered using the non-local means approach. This kind of filter makes
use of the information of all pixels in the image allowing to denoise the region
while preserving its details. Multi-phase level set funtion is used for evolving a
curve in the area of interest. This kind of level set approach comes in handy in
presence of very large kidneys since it avoids to have overlapping areas. This
approach makes the method suitable for the segmentation of kidney of different
size and so of patient at different disease stage. Starting from the mid-slice
this kind of segmentation is operated forward and backward in the remaining
images. In each image, the level set is initialized based on the position of the
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kidneys detected in the previous image.
Figure 3.3: Example of the detection of the renal regions in one patient.
3.2.2 Cyst detection
Beeing available the renal contouring and considering that in CT pixel intensity
of cysts are lower respect to parenchyma, a three class clustering based on fuzzy
c-means approach is used to outline the cystic area (figure 3.4). Similary to
TKV, TCV is computed as the sum of the voxel count and considering the
image resolution.
Figure 3.4: Example of the detection of renal and cystic regions in one pa-
tient.
3.2.3 Results
In this study one radiological reader manually traced the kidneys of each pa-
tient. Kidney volumes from automated and manual tracing were computed
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multiplying the area of the renal contour of each image and the slice thickness.
The agreement between the two methods were evaluated using linear regression
analysis, Bland-Altman plots and dice similarity coefficient. Regression analysis
(figure 3.5, top panel) showed a strong correlation between manual and auto-
mated volume estimation (r2 = 0.99; y = 0.99x-16.9). Bland-Altman analysis
(figure 3.5, bottom panel) showed a low bias ( -23.2 ml; -1.33%) and limits
of agreements of 72.9 ml ( 4.2%). Absolute mean percentage error resulted in
6.2±4.8%. The reliability of this approach in terms of dice coefficient value was
0.91±0.03.
3.2.4 Discussion and conclusion
In this preliminary study it has been presented a novel fully automated method
for ADPKD kidney segmentation on non contrast enhanced CT and showed
how it is promising for facilitating kidney volume assessment. Cyst volume was
excluded from the statistical analysis because in some kidney the parechyma
was completely replaced by the cysts. TKV is recognized as the best biomarker
for the evaluation of the progression of ADPKD disease. It has been proposed
for ADPKD patient classification [42] and used for the evaluation of the pro-
gression of the disease in several clinical trials like [55, 15]. Despite the great
interest of clinicians in the avalability of a method for polycystic kidney seg-
mentation on CT, nowadays only two semi-automated approaches have been
proposed [51, 53]. Both these methods use minimal user interaction and have
been tested on contrast enhanced CT. Our method is no user dependent and
it has been developed on non contrast enhanced CT and so avoiding the use
of contrast medium. Further investigations will be necessary to properly assess
the robustness of our method on a larger dataset.
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Figure 3.5: Linear regression (top panel) and Bland-Altmann (bottom panel)





In this chapter two research projects focused on diffusion imaging in MRI are
described. This innovative imaging technique which is commonly used in cere-
bral imaging could have important implications in different clinical scenarios
including ADPKD and cancer patients.
The idea of investigating water motion can be exploited from different point
of views and at different levels. Diffusion weighted imaging (DWI), diffusion
tensor imaging (DTI) and intravoxel incoherent motion (IVIM) are three dif-
ferent approaches for providing different types of information for a functional
characterization of a tissue trough the analysis of molecular diffusion of water
and microcirculation of blood in the capillary network. Therefore in these two
projects, that are strongly linked with the main research project developed in
this Thesis, we investigate the potentiality of DWI, DTI and IVIM for providing
functional information allowing to improve diagnosis and prognosis of ADPKD
and cancer patients .
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4.1 Diffusion tensor imaging of the kidney
This preliminary study was conducted to assess the feasibility of diffusion tensor
imaging (DTI) for the characterization of cortex and medulla in an healthy
population, as a first attempt to understand if DTI could be a useful for the
evaluation of kidney function.
4.1.1 Diffusion tensor imaging
Diffusion-weighted imaging (DWI) is a non-invasive method for the analysis of
the Brownian motion of water molecules in the extracellular space. Using DWI
sequences, the apparent diffusion coefficient (ADC) can be measured. This
quantitative parameter reflects cell density and microcirculation of the tissue
allowing the evaluation of various abnormalities [56, 57, 58]. ADC is derived
from the equation
ADC = −ln(Si/S0)/b
where b is the b value, Si is the signal intensity of the image for a specific b
value and diffusion gradient direction and S0 is the signal intensity of the image
without diffusion weighting.
ADC analysis is based on the assumption of free-molecular diffusion resulting
in a too semplicistic model especially in the presence of organized structures in
the tissue where the molecolar diffusion follows preferential directions. In the
kidney, tubules, collecting ducts and vessels radially oriented towards the pelvis
are responsible for diffusion anisotropy [59, 60].
Diffusion tensor imaging (DTI) is a particular MRI technique that allows the
measurement of the degree of anisotropy and structural orientation in the tissue.
The three-dimensional mechanisms of diffusion are described by the diffusion
tensor. To quantify the degree of anisotropy, the diffusion model can be mod-
eled by an ellipsoid represented by a tensor [61]. Eigenvalues of the diffusion
tensor represent the principal diffusivities and are associated with three mutu-
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ally perpendicular principal directions (eigenvectors). The tensor is represented







Being Dxy=Dyx, Dxz=Dzx and Dyz=Dzy, the tensor can be constructed using
six diffusion-weighted images acquired along different directions. The diffusion
tensor is calculated by solving the Stejskal-Tanner equation:
Sk = S0exp(−bgTkDgk)
where Sk is the signal intensity when a gradient pulse is applied in the direction
gk, S0 is the signal intensity measured with no diffusion-sensitizing gradient
and b is a factor describing the pulse sequence, gradient strength, and physi-
cal constants [62, 63]. The equation represents the signal attenuation due to
the application of a pulse gradient. In order to calculate the 6 independent
components in the 3x3 symmetric matrix D, at least 7 images are needed: 6
diffusion-weighted images from 6 gradient directions (providing 6 values for Sk














where d is the column vector of D
d = [Dxx, Dyy, Dzz, Dxy, Dxz, Dyz]
T
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Then, diffusion tensor can be obtained considering:
(H−1H)d = d = H−1Y
Several scalar measurements can be obtained computing eigenvectors (e1,e2,e3)
and eigenvalues (λ1,λ2, λ3) of the tensor from the diffusion tensor.
The mean diffusivity (MD) is a rotationally invariant measure of the magnitude
of diffusion.
MD =





The fractional anisotropy (FA) is a normalized measure of the fraction of
the tensor’s magnitude due to anisotropic diffusion
FA =
√






The radial diffusivity (RD) is a measure of the diffusivity along the directions
that are orthogonal to the principal one.
RD = (λ2 + λ3)/2
The volume ratio (VR) measures the ratio between the volume of the ellip-
soid and the volume of a sphere of radius MD




Ten subjects with age 33±12 and normal renal function estimated by GFR
(mean 88 mL/min) with no history of renal disease, hypertension, diabetes or
other vascular diseases underwent MRI. MRI images were obtained with a 1.5-
T whole-body system (Signa HDxt; General Electric, Milwaukee, USA) and
a standard phased-array body coil. The sequence was a spin-echo single-shot
echo-planar imaging (SSEPI) acquired in the axial plane with breath hold. The
MRI protocol is shown in table 4.1.
Repetition Time 3000 ms
Echo Time 82 ms
Field of view 40 cm
Slice thickness 6 mm
Gap 0.5 mm
Matrix size 128x128 px
Number of slices 14
b values 0 and 500 s/mm2
Number of gradients 6
Table 4.1: MRI protocol
Regions of interest were manually defined in cortex and medulla of the kid-
neys of each patient and MD, FA, VR computed using the procedure previously
described. A p-value <0.05 was considered statistically significant.
4.1.3 Results
In tables 4.2 and 4.3 the mean values obtained for the computed DTI param-
eters, for cortex and medulla respectively, are presented.
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Parameter Right kidney Left kidney p-value
MD (x10−3mm2/s) 2.70±0.36 2.68±0.31 0.77
FA 0.34±0.10 0.4±0.16 0.13
VR 0.15±0.1 0.21±0.16 0.14
Table 4.2: DTI parameters from renal cortex
Parameter Right kidney Left kidney p-value
MD (x10−3mm2/s) 2.47±0.31 2.45±0.21 0.87
FA 0.36±0.09 0.47±0.14 0.01
VR 0.16±0.07 0.29±0.17 0.02
Table 4.3: DTI parameters from renal medulla
4.1.4 Discussion
Mean values of the DTI parameters are in line with those published in recent
studies [60]. The results show also a significative difference in FA (p=0.01) and
VR (p=0.02) in renal medulla, between left and right kidney. This difference
may be due to a functional or structural difference in the kidneys. Similar
difference was found in [64]. A larger study population is needed for confirming
and better investigate this matter.
4.2 Diffusion-weighted MRI in the assessment
of ADPKD disease
In this preliminary study we investigated the feasibility of functional parameters
derived from DWI analysis for providing therapeutic indication for patients
in the first stages of the disease or surgical indications and check for those
patients with end-stage chronical disease that are candidates for nephrectomy.
This is part of an ongoing collaboration between the University of Bologna
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and the Ospedale Sant’Orsola of Bologna (Italy) which involves bioingineers,
nefrologists, radiologists and pathologists.
4.2.1 Case of study
The first case of study was an ADPKD patient candidate for nephrectomy. For
this 42 years old female patient, the removal of the organ was required because
she was suffering a great deal of pain and the enlargement of the kidneys caused
an important burden in the abdomen.
4.2.2 In-vivo and ex-vivo analysis
Before surgery, morphological and functional MR images of the abdomen were
acquired.
Figure 4.1: Two images in coronal (left panel) and axial (right panel) views of
the kidneys.
T2-weighted and diffusion-weighted images (figure 4.1) were acquired.
After surgery, the volume of the explanted polycystic kidney (figure 4.2) was
estimated through Archimede’s principle and resulted in about 5000 ml. Ul-
trasound analysis was performed in order to investigate the possibility of the
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Figure 4.2: A picture of the explanted kidney.
Figure 4.3: Anatomical specimens of the explanted kidney before formaline
filling.
presence of residual parenchyma. Renal cyst fluid was aspired by the pathol-
ogist from those cysts positioned in the exterior part of the kidney and that
could be easily identified in the MR images. The kidney was then dissectioned
and several specimens extracted (figure 4.3).
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Figure 4.4: From left to right: S0, MD map, FA map
4.2.3 Results
Kidney volume was estimated via manual contour and using the semi-automatic
method described in the previous chapter and resulted in 5120 ml and 4962 ml,
variating from the empirical estimation of +2.5% and -0.76% respectively.
Mean diffusivity, fractional anisotropy and radial diffusivity were measured from
DWI data, highlighting the presence of normal parenchyma (figure 4.4). No nor-
mal parenchyma was detected using ultrasounds. Histological analysis showed
the presence of extended fibrosis but also 30% of normal tissue in the renal
specimens examined.
4.2.4 Discussion
Volume analysis allowed an in vivo validation of the semi-automated approach
for TKV computation. Surprisingly, histological examination confirmed the
presence of normal parenchimal tissue, which was not expected since morpho-
logical images showed that renal parenchyma was completely replaced by cysts.
Ultrasound appears to be not suitable for detecting any kind of parenchyma in
kidney with so many cysts. This study on a single patient represents a proof of
concept of the potential utility of using informations extracted from diffusion
tensor imaging for evaluating the presence of normal parenchyma. Actually,
histological analysis is the only technique available for this kind of analysis and
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the use of diffusion images may be aof value for providing additional functional
information applying a non invasive approach.
4.3 IVIM analysis of breast lesions
The expertise gained in the analysis of functional images was extended to the
study of breast lesions from intravoxel incoherent motion (IVIM) and dynamic
contrast-enhanced (DCE) MRI. In this study, perfusion and diffusion MRI met-
rics have been computed and analysed for the evaluation of breast lesions.
4.3.1 Introduction
Cancer is characterized by a high biological heterogeneity [65, 66, 67]. Such
heterogeneity has been confirmed in particular for breast cancer [68]. In this
contex, the avalability of biomarkers for quantitative analysis and differentiation
of lesions has become critical.
Conventional mammography is the most common modality for screening breast
cancer but has shown low sensitivity in particular in cases of dense breast
parenchyma [69]. In comparison with mammography, contrast-enhanced MRI
allows to study tissue perfusion by a quantitative analysis of pharmacokinetic
parameters showing high sensitivity but low specificity [70]. Recently, a lot of
interest has been put in DWI analysis for the differentiation between benign and
malign lesions. Furthermore, DWI acquisitions do not require the use of con-
trast medium and it has been seen that DWI parameters such as the apparent
diffusion coefficient (ADC) is able to differentiate breast lesions [71]. However,
the sensitivity and specificity among different studies can vary a lot [71, 72, 73]
also because of the choise of different maximum b-values that can lead to an
overestimation of ADC [74]. IVIM technique makes use of multi b-value DWI
and is able to provide separated information about perfusion and diffusion [75].
Nowadays only few studies have explored the capability of this technique in the
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differetiation of breast lesions but the preliminary results are promising. Aim of
this study was to evaluate the diagnostic potential of IVIM and DCE for breast
lesions.
4.3.2 Image analysis
ADC maps were obtained assuming the monoexponential model for diffusion-
weighted images at all b-values:
S(b) = S0exp(−bADC)
where b is the b-value and S0 and S(b) denote the signal intensity of diffusion-
weighted images acquired with b-value of zero and b respectively.
To compute the IVIM parameters was used the biexponetial model as de-
scribed by Bihan [75] :
S(b) = S0[(1− f)exp(−bD) + fexp(−b(D +D∗)]
where f is the perfusion fraction representing the microvasculare volume frac-
tion, D is the true coefficient representing the pure water molecular diffusion and
D∗ is the pseudodiffusion coefficient representing which reflects the perfusion-
related diffusion (incoherent microcirculation). Several calculation methods
have been proposed for the computation of these parameters and among them
there are [76, 77, 78]. In this study, considering the relatively few number of
b-values, it was used the segmented approach [76] which is also considered more
robust than the simultaneous full fitting [79, 80].
The segmented approach is based on the assumption that being D∗ greater then
D its effects on the signal decay at large b is negligible. D is determined from
data within on interval of high b-values (b >200 s/mm2) using the least squares
curve fit:
Shigh(b) = Shigh0(1− f)exp(−bD)
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where Shigh0 = S0(1−f). Then f is determined from S0 as f = (S0−Shigh0)/S0.
Finally D∗ is obtained from the monoexponential fit using the precalculated D
and f . The goodness of the fit was evaluated using the R2 value:
R2 = 1− SSE/TSS
where SSE is the sum of squared erros between the data and the fitting curve
and TSS is the sum of squared differences between the data and the mean of all
data values. Voxels with R2 value above 0.8 were excluded from the analysis.
For each detected lesion, and for each parametrical map, as in was computed:
Quantitative analysis of ADC, f , D, D∗ included: mean and standard de-
viation, median and quartiles, total numer of voxel included in the analysis,
total numer of voxel excluded from the analysis, skewness, kurtosis, contrast,
correlation, energy, homogeneity.
DCE analysis was performed constructing a time intensity curve (TIC) for
each detected lesion. Quantitative analysis included: wash-in slope, wash-out
slope, absolute percentage enhancement, time to maximum enhancement, con-
trast, correlation, energy, homogeneity.
In figure 4.5 is illustrated the interface developed for IVIM and DCE analysis
from MRI.
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Figure 4.5: Interface for IVIM and DCE analysis from MRI
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